STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway
Genes & Development · 01.07.2026 · 40 (13-14) · 1080-1098
DOI: 10.1101/gad.353309.125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Development, online erschienen am 13.05.2026. Verfasst von Jeongmin An und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental and Cell Biology, University of California, Irvine, Irvine, California 92697, USA. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Signal Transduction, Drosophila Proteins, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The Hippo pathway is a key regulator of development, regeneration, tissue homeostasis, and organ size, and its dysregulation promotes tumorigenesis. However, the precise mechanisms of its regulation in both normal physiology and cancer remain incompletely understood. Here, we identify STK38 and STK38L (also known as NDR1 and NDR2), previously proposed as redundant kinases of LATS, as negative regulators of the Hippo pathway. STK38/L inhibit LATS by competitively binding to MOB1 and disrupting the LATS–MOB1 complex, a process independent of their kinase activity. This inhibitory mechanism is evolutionarily conserved, as the Drosophila ortholog Tricornered similarly impairs Warts–Mats complex formation, resulting in enlarged fly wing size. Pathologically, STK38L is highly expressed in ovarian cancer and required for ovarian tumor growth, and its amplification correlates with YAP activation and increased tumor sensitivity to TEAD inhibitors. Taken together, our study reveals a conserved role of STK38/L in Hippo pathway regulation, providing new insights into Hippo-dependent growth control and cancer development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Developmental and Cell Biology, University of California, Irvine, Irvine, California 92697, USA.
- Chemical and Materials Physics Graduate Program, University of California, Irvine, Irvine, California 92697, USA.
- Department of Biomedical Engineering, University of California, Irvine, Irvine, California 92697, USA.
- Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, California 92697, USA.
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, Irvine, California 92697, USA.
- Department of Materials Science and Engineering, University of California, Irvine, Irvine, California 92697, USA.
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- National Institutes of Health
- National Cacner Institute
- University of California, Irvine, Chao Family Comprehensive Cancer Center
Zitieren
APA
An, J., Huang, Z., Kizhedathu, A., Lan, T., Lin, T., Joo, H., Thilakaratne, E. M., Liu, Y., Xu, Y. Y., Yang, B., Lara-Gonzalez, P., Warrior, R., Luo, R., & Wang, W. (2026). STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway. Genes & Development, 40(13-14), 1080-1098. https://doi.org/10.1101/gad.353309.125
Vancouver
An J, Huang Z, Kizhedathu A, Lan T, Lin T, Joo H, et al. STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway. Genes & Development. 2026;40(13-14):1080-1098. doi:10.1101/gad.353309.125
BibTeX
@article{An2026,
author = {An, Jeongmin and Huang, Zhen and Kizhedathu, Amrutha and Lan, Tian and Lin, Tzuling and Joo, Hyejin and Thilakaratne, Eshan Malinda and Liu, Yuhan and Xu, Yun Yi and Yang, Bing and Lara-Gonzalez, Pablo and Warrior, Rahul and Luo, Ray and Wang, Wenqi},
title = {STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway},
journal = {Genes & Development},
year = {2026},
volume = {40},
number = {13-14},
pages = {1080--1098},
doi = {10.1101/gad.353309.125}
}
EUVIMED